You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The "EV Click Chip" process involves collecting and purifying extracellular vesicles from a blood sample before performing RT-ddPCR to identify up to 10 early-stage HCC biomarkers.
The Minneapolis-based firm believes the assay can successfully serve as a clinical indicator for patients at risk of developing high-grade prostate cancer (HGPC), thereby improving prostate cancer management.
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
The team has begun analyzing additional analytes in HER2-positive breast cancer patients and will present preliminary results at AACR's annual meeting in May.
Boston-based NanoView aims to make its extracellular vesicle detection technology more widely available for research and biomarker discovery.
The group will validate Miraca's prototype extracellular vesicle isolation tool and antibody reagents using blood samples from breast and pancreatic patients.
The Boston-based company is working to make its extracellular vesicle detection technology more widely available for research and biomarker discovery.
As part of the collaboration, researchers will study exosomes in cancer patients and individuals who have a high genetic risk for cancer.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.